biomed devic servic
biomed devic servic
price close busi may
ortho earn preview busi two week queu
enter second major week med-tech earn thing pretti
unev given major coverag univers alreadi pre-announc
withdrawn guidanc gener consensu gather
manag team investor quickli character
throw-away year winners/los unlik shine earli
fall point better view near/medium term econom
impact pandem clariti around durabl defer procedur
demand impact capital-expenditure cycl hospit system
capac elect procedur broadli manag team cut too-
deepli tri minim cash burn said still away
answer major question least focu
shift recoveri suggest investor pay attent qualit
commentari earn cycl respect commerci stabil rep turnov
 invest clinic trial impact pace durabl
oper recoveri
learn thu far
simpli put view continu like show lsd declin much
covid-impact felt follow sharp improv year
procedur final catch earli
brunt impact felt recent april survey also
indic averag practic volum declin april expect
declin may june respect patient visit
continu via telemedicin era social distanc orthopedic/spin
busi model obvious center around surgeri elect
procedur defer importantli first week may seen
state loosen restrict elect surgeri bode well
return product exit
nevertheless expect sharp rebound back half year
albeit weight survey respond expect volum
remain depress also note recoveri expect take
averag week flatten curv view given
import orthoped revenu hospit ls fact mani
privat practic struggl meet payroll/offic expens provid like
perform surgeri nights/weekend order make procedur volum
earli dynam seen play prior year respons natur
disast albeit time period sever week rather multipl month
appetit capit like challeng declin
procedur volum impact hospit system much devic
manufactur simpli put mani deferr procedur repres highest
margin busi unit hospit feder govern step
financi assist expect continu believ distress
natur mani health system neg impact demand larg capit
purchas next sector mean robot imag
navig major focu total joint spine compani
may serv acceler shift toward bundl give capit away
up-front return contract implant util
follow page present detail look orthoped
compani report next week along summari estim chang
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
biomed devic servic
alreadi report preliminari result vs consensu
withdrew guidanc contempl disrupt
said clear sever impact abrupt declin
procedur global believ pure play focu spine posit compani
better diversifi peer least rel basi given lack
distract compet corpor prioriti
substanti trauma busi estimate rev normal insul
procedur volatil earli commentari suggest trauma volum
equal impact dynam social distanc less car crash construct
relat accid sport relat injuri mix feel
candidli still work thought nuva domin xlif
complex/mi thoraco/lumbar spine posit compani post-covid
rebound procedur profit physician hospit
thu priorit also requir signific resourc larg
unabl move asc/outpati set may prove rel
headwind least near-term health system lean outpati set
improv oper capac lastli appear dodg capit
equip bullet sens expect puls push
previou call compani face near-term uncertainti hospit
demand capit purchas given impact covid health system
continu believ remain attract name robust new product flow
stable/improv us spine market ex impact continu ou share
take clear lt margin expans road map ahead
withdrew guidanc previous y/i revenu growth earli
april due on-going disrupt covid note
impact normal commerci activ like attend surgeri educ
physician also reduc incid traumat injuri social
distanc shelter in-plac polici kept mani peopl insid across us
note lack activ direct commerci sale well in-person
medic educ potenti impact pace execut
product expans sale forc key aspect growth thesi
someth focu call respect share much
chang last week still believ share oversold still
year alon suggest investor move cautious given compani
struggl appropri set guidanc recent year someth may continu
given uncertainti end market regardless compani remain
well capit differenti product strong margin profil
insul downsid risk current level ev/sal net net
continu advis investor let dust settl take harder look
realist growth backdrop still compani prior
covid grow revenu solid balanc sheet
alreadi pre-announc result revenu expect rang
vs consensu withdrew guidanc previous
call growth y/i believ pureplay focu spine recent
biomed devic servic
product launch upgrad distribut channel posit compani well
rebound quickli disrupt eas note clean
balanc sheet cash access debt provid
ampl war chest withstand near-term slowdown go offens quickli
look preliminari result clear compani carri momentum
underli product improv fall elect surgeri
began postpon march long-term basi continu believ
posit grow multipl broader spine market
recent/upcom product launch provid opportun take share
entrench larg compani well particip consolid smaller
fragment me-too player given share alreadi cheap prior sell-off
view trade ev/sal advis investor give
anoth look begin move broader downturn
given assumpt around covid impact thesi emerg
diversifi ortho player growth trauma joint like push
expect capit sale cycl heavili impact
covid underli procedur slowdown like serv headwind
growth said clean balanc sheet cash
debt expect mayb hope better word compani emerg
strateg acquiror post-covid environ addit believ covid may
serv rip band-aid moment mani capit purchas shift
toward bundl util agreement procedur share implant
biolog thu potenti set core spine outsiz growth
beyond pre-covid unit placement continu strong increasingli
optimist underli momentum core us busi particularli given
opportun continu implant pull competit robot placement
robust product pipelin long-term acceler ou
momentum particularli japan despit delay growth continu view
underli opportun spine posit see earli potenti
breakthrough period emerg diversifi ortho player
drive meaning growth trauma total joint capital-expenditure robots/imag
top core spine busi net net unlik pretti
wont blame investor wait better entri point near-term
said compani manag team strong strateg vision
ampl non-dilut financi resourc hand best-in-class oper profil
support lt view buy
withdrew full year guidanc earli april pre-announce revenu
expect declin xfx player knee hip
signific exposur deferr procedur global believ
on-going roll-out rosa like exacerb near-term revenu weak given
revenu expect capit placement well pull-through benefit
implant simpli put expect rosa impact perhap
given cash flow constraint hospit custom fact
physician like focus procedur throughput rather learn
curv new robot longer term howev continu view posit
biomed devic servic
believ structur oper cultur turnaround alreadi taken root
invest improv suppli chain new product flow persona line
extens rosa put compani posit go offens elect
procedur rebound someth expect happen major way
share sinc trough mid-march albeit still
feb high wouldnt surpris see investor wait clariti
impact near-term cash burn time oper turnaround
think build ad posit
pre-announc strong revenu cg/street estim pull
guidanc earli april similar atec pureplay posit recent
product launch includ safeop posit compani quickli return share-
take covid impact reced addit compani recent termin
tender offer agreement eo imag remov like overhang given
uncertainti around hospit capital-expenditure environ overal prior
see clear evid new product gain traction growth
sale forc acceler compani captur increas share
procedur revenu expect continu econom shock
subsid said surpris see investor take time
given on-going disrupt surround impact us procedur
volum uncertainti regard vorac time rebound
revis estim sever ortho compani advanc
earn announc week earli next week obvious revisit
model compani report week want get head start
stock
lower full year revenu estim reflect preliminari
result well updat procedur volum expect remaind
model revenu
previou pre-pandem estim lower
revenu estim previous
given signific revenu impact expect gross margin challeng
next month fix overhead spread lower volum
near-term higher per-unit price work inventori channel
said expect declin y/i sharp y/i increas
modestli reduc oper spend expect previous
announc initi minim cash burn effort off-set near-term
impact
biomed devic servic
figur summari chang estim
lower full year revenu estim reflect preliminari
result well updat procedur volum expect remaind
model revenu
previou pre-pandem estim model
revenu previous
modestli reduc oper spend expect cost
contain initi across compani particularli sg counter
near-term impact
figur summari chang estim
except ep newold newold newold revenu breakdownu spinal surgic operatin ebitda net except ep newold newold newold revenu profit oper biomed devic servic
lower full year revenu estim reflect updat procedur
volum expect remaind model
revenu previou pre-pandem estim
model revenu
expect emerg technolog sale excelsiu robot advers
impact given expect cash flow constraint prospect hospit
custom fact physician like focus procedur
throughput rather learn curv new robot said
model enabl technolog revenu
previou estim
modestli reduc oper spend expect near-term
invest delay cost-cut measur sg counter
near-term impact
figur summari chang globu estim
zimmer reclassifi sever busi units/product line
rebuilt model base new report structur
lower full year revenu estim reflect preliminari
result well updat procedur volum expect remaind
model revenu
previou pre-pandem estim model
revenu previous
updat oper model assum lower oper spend near-
term invest across sg expect period reduc
discretionari spend persist least
except ep newold newold newold revenu operatin ebitda net
biomed devic servic
figur summari chang zimmer estim
lower full year revenu estim reflect preliminari
result well updat procedur volum expect remaind
model revenu
previou pre-pandem estim model
revenu previous
modestli reduc oper spend expect near-term
invest delayed/postpon effort off-set cash burn
except ep newold newold newold revenu spine -- y/i gross operatin ebitda net
biomed devic servic
figur summari chang estim
chang price target
adjust follow price target valuat reflect previou
alphatec nasdaq buy lower price target
base averag ev/sal multipl
appli revenu estim assum cash
debt share outstand valuat
globu nyse buy lower price target
base averag price-to-earnings ev/ebitda multipl
analysi updat estim price-to-earnings analysi appli
multipl ep ev/ebitda valuat appli
multipl ebitda estim price target assum
cash debt share outstand
nasdaq buy lower price target
base averag price-to-earnings ev/ebitda multipl
analysi updat estim price-to-earnings analysi appli
multipl ep ev/ebitda valuat appli
multipl ebitda estim assum cash
debt share outstand valuat
seaspin nasdaq buy lower price target
base averag ev/sal multipl appli
revenu estim assum cash debt
debt share outstand valuat
zimmer biomet nyse buy lower price target
base price-to-earnings multipl appli pro-
forma ep
except ep newold newold newold revenu profit operatign figur nuvas incom statement
biomed devic servic
-- quarterli incom statementcanaccord genuiti kyle except y/i q/q good market one-tim oper oper incom tax loss attribut non-controlling incom loss share percentageproforma rate growth oper oper adjust figur seaspin incom statement
biomed devic servic
seaspin incom statementcanaccord genuiti kyle except oper oper time oper non income/ expens net analysisgross compani document canaccord genuiti estim figur globu medic incom statement
biomed devic servic
globu medic inc -- quarterli incom statementcanaccord genuiti kyle except good litig oper ex oper ex chg tax incom ex one-tim chg incom ex one-tim share analysisgross litig w/redemp oper changetot changetot figur zimmer biomet incom statement
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex figur alphatec incom statement
biomed devic servic
alphatec incom statementcanaccord genuiti kyle except oper oper time oper non income/ expens net analysisgross gross incom compani document canaccord genuiti estim biomed devic servic
